The COVID-19 pandemic has turned RNA into a household word, but what new innovations and changes will we see in the RNA therapeutics space going forward and how many will actually reach the clinic?
Agreement grants Eterna rights to license up to four next-generation iPS cell derived NK and T cell cancer therapies.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for funding RNA-based cell therapies as a panel member at the RNA Cell Therapies Summit.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will participate in an industry leader fireside chat focused on “Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies and Determining Future Outlook and Developments” at the 2nd iPSC-Derived Cell Therapies Summit.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Strategies to Develop Safe Cell Therapies Without Compromising Efficacy” at the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join an expert panel of biotechnology leaders to discuss “Placing Patients at the Center” during the Longwood Healthcare Leaders Fall webconference.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Leveraging mRNA Based Gene Editing to Optimize Advancement of Safe and Cost-Effective IPSC Products” as part of the focus track on Innovations in Gene Engineering and Editing at the 7th Annual CAR-TCR Summit in Boston on September 19, 2022.
Five RNA Therapeutics Startups to Watch in 2022
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference.
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for optimal positioning of new therapies as a panel member at the Cancer Progress Conference.